Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 4.7
Power Rank trend -> Falling
Industry: Medical Instruments & Supplies
Follow @stockchartsai on TwitterIn the past 20 trading days, RMD has been trading in a range between $257.65 and $228.83 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
The AI powered stock chart is in a Red zone currently. We would avoid this stock.
ResMed Inc $RMD entered a Red zone 1 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $256.0236, a potential upside of 8.05% from the recent price of 236.94. The stock is trading 11.02% (potential upside) below its 52 week high of $263.05 and 39.86 % (potential downside) above its 52 week low of $169.41 - based on the recent price.
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service.
Jan De Witte joins GHO Capital as Operating Partner Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Source: GlobeNewsWire Tue, 11 Feb 2025 04:30:00 -0500 Sentiment: Neutral |
Why ResMed (RMD) is a Top Growth Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. Source: Zacks Investment Research Mon, 10 Feb 2025 10:47:19 -0500 Sentiment: Positive |
Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions ResMed reported $1.28 billion in revenue and $2.43 EPS, driven by strong demand for AirSense 11 and effective cost management. Rising awareness of sleep apnea, aided by wearable devices like Apple Watch, underscores a significant growth opportunity, with millions still undiagnosed and untreated globally. Concerns over GLP-1 drugs reducing CPAP demand have diminished. Source: Seeking Alpha Mon, 10 Feb 2025 10:38:23 -0500 Sentiment: Positive |
Trump Tariffs Threaten MedTech: 3 Stocks to Mitigate Risks Three companies that are better positioned to withstand Trump's tariff challenges are ResMed, Hims & Hers Health and Medtronic. Source: Zacks Investment Research Wed, 05 Feb 2025 13:15:31 -0500 Sentiment: Negative |
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes" ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market. Source: Zacks Investment Research Tue, 04 Feb 2025 13:45:33 -0500 Sentiment: Positive |
Stock Analyzed Each Night
Easily Upload Track Your Stocks
See Lists of Stocks Starting New Trends
The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.